Elutia Posts $1.1M Q3 Sales, Confirms NXT-41x FDA Filing This Quarter With $29.1M Cash
ELUT sits 50% above its 52-week low of $0.5.
Summary
Elutia reported third-quarter net sales of $1.1 million, up 20.4% from $0.9 million a year earlier, with adjusted gross margin of 85.5%. Net loss narrowed to $1.3 million from $3.9 million, helped by $5.2 million of income from discontinued operations, while the continuing-operation loss widened to $6.5 million as R&D spending rose $1.9 million on the NXT-41 and NXT-41x programs. Cash stood at $29.1 million at September 30, before the $8 million Boston Scientific holdback received October 1. Management says the three August funding moves — the Avenue Capital loan, the SimpliDerm sale and the escrow release — added $26 million in 51 days without an equity offering, enough to fund operations through NXT-41x clearance and its first full launch year. The near-term driver is regulatory: NXT-41 clearance is expected this quarter and the NXT-41x submission is planned for Q4 2026, with a clearance decision anticipated in the first half of 2027. The company still faces a Nasdaq minimum-bid issue with the stock at $0.75, and a Cardiovascular sale process is targeted for 2026 but is not needed for the stated runway.
At the time of this announcement, ELUT was trading at $0.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.3M. The 52-week trading range was $0.50 to $1.39. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.